Eli Lilly and Company (LLY) : Mondays money flow indicated an uptick to downtick ratio was at 1.72. The total value of inflow transactions on upticks was $51.32 million, whereas, the total value of outflow trades on downticks was $29.8 million. The total money flow was $21.52 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $20.05 million. The total value of the trades done on upticks was $26.51 million. Downticks saw transactions worth $6.46 million. The total uptick to downtick ratio stood at 4.1, mildly in favor of the bulls. Eli Lilly and Company (LLY) was trading with a -0.42% change over previous days close. It fell $0.34 during the day and reached $80.22. The stock was -1.64% compared to the previous weeks close.
Eli Lilly and Company has dropped 1.02% in the last five trading days, however, the shares have posted positive gains of 0.69% in the last 4 weeks. Eli Lilly and Company is up 3.17% in the last 3-month period. Year-to-Date the stock performance stands at -2.83%.
Eli Lilly and Company (NYSE:LLY): During Mondays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $80.33 and $80.07 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $80.62. The buying momentum continued till the end and the stock did not give up its gains. It closed at $80.26, notching a gain of 0.05% for the day. The total traded volume was 2,780,381 . The stock had closed at $80.22 on the previous day.
In a related news,The officer (Chief Accounting Officer) of Lilly Eli & Co, Zakrowski Donald A sold 1,213 shares at $83.16 on July 28, 2016. The Insider selling transaction had a total value worth of $100,873. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.